Brought to you by 
ProUroCare nets $2.7mm via public offering
14 Jan 2009
Executive Summary
ProUroCare Medical (diagnostic devices for prostate disease) netted $2.7mm through the follow-on public offering of 3.05mm units at $1.00 apiece. Each unit is comprised of one common share and one warrant to buy one share exercisable at $1.30. The company will use part of the money to gain 510(k) clearance of its ProUroScan prostate imaging system.
Deal Industry
- Medical Devices
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ProUroCare nets $2.7mm via public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice